A Study of ADRX-0706 in Select Advanced Solid Tumors

Description

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.

Conditions

Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.

A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors

A Study of ADRX-0706 in Select Advanced Solid Tumors

Condition
Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

Los Angeles

UCLA, Los Angeles, California, United States, 90404

Saint Petersburg

Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States, 33709

Grand Rapids

START Midwest, Grand Rapids, Michigan, United States, 49546

Nashville

Sarah Cannon Cancer Network, Nashville, Tennessee, United States, 37203

Houston

University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030

San Antonio

START San Antonio, San Antonio, Texas, United States, 78229

West Valley City

START Mountain Region, West Valley City, Utah, United States, 84119

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Phase 1a Dose Escalation: Subjects with histologically confirmed select advanced solid tumors, including urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), breast cancer, cervical cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. Subjects must have received at least one prior systemic regimen and have no other therapy available known to provide meaningful clinical benefit in the opinion of the investigator.
  • * Measurable disease according to RECIST version 1.1
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * Adequate hematologic, liver, and renal function
  • * Active and uncontrolled central nervous system metastases
  • * Significant cardiovascular disease
  • * History of another malignancy other than the one for which the subject is being treated on this study within 3 years
  • * Receipt of any anticancer or investigational therapy within 5 elimination half-lives or 14 days (whichever is less)
  • * Any P-gp inducers/inhibitors or strong CYP3A inhibitors received within 14 days prior to the first dose of study drug
  • * Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Adcentrx Therapeutics,

Study Record Dates

2026-12